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MicroRNA’s are short RNA sequences between 22 – 24 
nucleotides in length that target complementary messenger-
RNA (mRNA) transcripts and prevent them from being 
translated into proteins. With thousands of different miRNA’s 
in the body, they form an expansive regulatory network which 
is crucial for proper cell development and function (1). 
Altered microRNA expression is believed to play a role in 
many diseases, including cancer. In all forms of cancer, 
miRNA expression levels are noticeably different, and these 
alterations vary by cancer type. This study focuses on 
microRNA-503 and its alleged role in intracellular 
communication between tumorigenic cancer cells and healthy 
body cells.  
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Figure 1:  Basic overview of post-
transcriptional microRNA regulation (1) 
A common characteristic shared by many cancer types is a 
lack of immune response in regions of tumor growth due to the 
immune cells’ inability to recognize or target cancer cells. It is 
widely believed that tumor cells send signals to the body 
immune cells to retard their overall function and promote 
uncontrolled tumor proliferation. CD28 (shown below) is a 
signaling protein found on the extracellular membrane of T-
cells, and is involved in T-cell activation and proliferation (2). 
CD28 levels have been found to be reduced in T-cells that are 
present in the tumor microenvironment, likely due to signaling 
that occurs between the T-cells and cancer cells. 
MicroRNA-503 matches a complementary sequence on the 
CD28 mRNA transcript, and is significantly upregulated in 
Colon Cancer (3). 	

Figure 2:  CD28 T-cell receptor protein (2)	
The purpose of this 
study was to confirm 
that miR-503 targets 
the CD28 protein and 
reduces its expression. 
Conformation of this 
regulatory 
relationship would 
open up the 
possibility that 
miR-503 is involved 
in the  signaling 
pathway that causes 
T-cell deactivation in 
the tumor 
microenvironment. 	

Several experiments were done in an effort to generate data 
indicating CD28 targeting by miR-503. The final experiment 
that gave strong evidence for CD28 targeting is outlined 
below:	

	

Ø  Jurkat T-cells were used as an experimental model, as they 
are human leukemia cells and thus have lowered CD28 
levels. Using anti-microRNA’s we reduced the levels of 
microRNA-503 in the T-cells to observe the resulting 
effect on CD28 levels. 	

Ø  Experiment Overview:	

 
Obtained Jurkat T-cells, MZ plasmid vector, and anti-
microRNA’s: miRzip-182 and miRzip-503 
Insert Anti-miR genes into MZ vector, confirm by 
restriction digest. Clone vectors containing inserts 
with PCR 
Transfect Jurkat T-cells with MZ vectors 
containing anti-miRNA’s and empty MZ control 
vector 
Extract Jurkat T-cell proteins and 
determine protein levels with BCA Assay. 
Run Western Blot with anti-CD28 
antibody using beta actin control. CD28 
Approximately 46 daltons. 
Figure 3: General Overview of Western 
Blotting Protein Detection Technique (4)	

*Additional experiments were done in analyzing 
miR-503 involvement in T-cell deactivation in the 
presence of tumors.  
MZ ctrl           MZ183         MZ503 
Jurkat 
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CD28, 44kda 
Beta actin, 
45 kda 
-    Lane 1 shows untreated Jurkat T-cells 
-  Lane 4 shows miRzip-503, high intensity of the     
     band at 46 kDa indicates higher levels of CD28. 
-  Second set of Westerns had low protein levels as  
     indicated by the faintness of the CD28 bands.   
	

 	

	

-  Lanes 1 & 2 show healthy T-cell CD28 expression levels 
at 46 kDa. 	

-  Lanes 3 & 4 show CD28 levels of T-cells col-cultured 
with Colon Cancer cells. 	

-  Faint bands in Lanes 3 & 4 indicate reduced CD28 
levels. 	

While additional experimentation must be done to confirm 
CD28 as a target of miR-503, the western blot data we obtained 
strongly supports this conclusion. The image above is a close 
up of the CD28 bands in Figure 4 for the Jurkat T-cell 
transfected with the empty MZ vector and MZ vectors 
containing anti-microRNA’s targeting miR-503 and miR-183, 
also believed to target CD28. The intensity difference in the 
bands between the untreated Jurkat T-cells and those with 
miR-503 inhibition is obvious; the restored CD28 levels serve a 
strong indication that miR-503 targets CD28.	

	

The western blot data in Figure 5 was a follow-up experiment 
to provide evidence that reduction of CD28 levels in T-cells is 
caused by cancer cells. Lanes 3 and 4 represent mouse T-cells 
that were cultured with colon cancer cells and show reduced 
CD28 levels compared to the healthy T-cells. This data 
indicates that colon cancer cells manipulate CD28 levels of 
healthy T-cells while grown in culture with them. In order to 
connect the dots between the outcomes of these two 
experiments it is essential to determine the signaling 
mechanism(s) cancer uses to alter the CD28 levels in T-cells. 	

	

A common hypothesis that has been both supported and 
rejected by researchers is intercellular exosomal delivery of 
genetic materials between cancer cells and body cells, such as 
microRNA’s and other regulatory elements (5). This is currently 
a focal point of Dr. Li’s study in how cancer cells are able to 
alter the function of T-cells in the tumor microenvironment. 
Cancer is a highly complex disease and while many of it 
mechanisms are poorly understood, they all essentially share 
the common characteristic of promoting tumor proliferation and 
metastasis. With reduced CD28 levels, T-cells are less capable 
of fulfilling their adaptive immune function, and this may very 
well be one of cancer’s many mechanisms for promoting its 
own growth and survival. If so, it is highly probable that 
microRNA-503 is involved in the process to some extent. 
However, more experimentation is necessary to confirm either 
of these hypotheses. 	

CD28 
Figure 5: Western Blot comparing CD28 levels between 
healthy mouse T-cells and T-Cells co-cultured with 
Colon Cancer cells. 	

Figure 4:  Final Western Blot of Jurkat T-cell transfected 
with anti-miRNA’s, CD28 at 46 kDa.  
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